Convergent Therapeutics

About Convergent Therapeutics

Convergent Therapeutics is a biotechnology company dedicated to developing next-generation targeted radiotherapies to improve the lives of cancer patients. Their mission is to unlock the full potential of alpha radioantibodies, making radiation therapy more targeted and effective.

Products & Services

Alpha Radioantibodies:Targeted radiotherapies using alpha-emitting payloads linked to proprietary antibodies to precisely target cancer cells while minimizing damage to healthy tissues.

CONV01-α:A specific alpha radioantibody therapy under clinical trial for cancer treatment, particularly focused on prostate cancer.

Specialties

Targeted Radiotherapies Alpha Radioantibodies Prostate Cancer Treatment Oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 90000000 MR: - FA: 90 million FAN: 90000000	D: 2023-05-03 FD: 2023-05-03	3 investors

Series A Latest

2023-05-03

$90.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Philip Kantoff

Chief Executive Officer, Co-Founder

N

Neil Bander

Senior Scientific Advisor, Co-Founder

A

Alex Brown

Chief Operating Officer

R

Richard Messmann

Chief Medical Officer

E

Eric M. Sullivan

Chief Financial Officer

S

Scott Myers

Board Member

View 9 more team members with Pro

Unlock Full Team Directory

Recent News